To Demonstrate the Superiority of IMP (1% OPA-15406 Ointment) to the Vehicle in Adult Patients With AD
Status:
Not yet recruiting
Trial end date:
2024-03-01
Target enrollment:
Participant gender:
Summary
This is a multinational (China and Korea), multicenter, randomized, double-blind,
vehicle-controlled, parallel-group, comparison trial to demonstrate the superiority of 1%
OPA-15406 ointment to the vehicle in adult AD subjects.